NASDAQ:BDSI - BioDelivery Sciences International Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$2.40 -0.10 (-4.00 %)
(As of 05/25/2018 04:00 PM ET)
Previous Close$2.40
Today's Range$2.35 - $2.60
52-Week Range$1.70 - $3.60
Volume672,648 shs
Average Volume451,639 shs
Market Capitalization$148.18 million
P/E Ratio-6.15
Dividend YieldN/A
Beta0.39

About BioDelivery Sciences International (NASDAQ:BDSI)

BioDelivery Sciences International logoBioDelivery Sciences International, Inc., a specialty pharmaceutical company, engages in the development and commercialization of pharmaceutical products principally in the areas of pain management and addiction. The company provides its products based on its patented BioErodible MucoAdhesive drug delivery technology, a small erodible polymer film for application to the buccal mucosa, as well as other drug delivery technologies. It offers BELBUCA, a buprenorphine buccal film for the treatment of chronic pain; BUNAVAIL, a buprenorphine and naloxone buccal film for the treatment of opioid dependence; and ONSOLIS, a fentanyl buccal soluble film to treat breakthrough pain in opioid patients with cancer. The company also develops buprenorphine extended release injection, an injectable microparticle formulation of buprenorphine for the treatment of opioid dependence and chronic pain. BioDelivery Sciences International, Inc. has a licensing and development agreement with Evonik Corporation and Meda AB. The company was founded in 1997 and is headquartered in Raleigh, North Carolina.

Receive BDSI News and Ratings via Email

Sign-up to receive the latest news and ratings for BDSI and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
SymbolNASDAQ:BDSI
CUSIP09060J10
Phone919-582-9050

Debt

Debt-to-Equity Ratio35.82
Current Ratio1.40
Quick Ratio1.13

Price-To-Earnings

Trailing P/E Ratio-6.15
Forward P/E Ratio-3.53
P/E GrowthN/A

Sales & Book Value

Annual Sales$61.99 million
Price / Sales2.29
Cash FlowN/A
Price / CashN/A
Book Value$0.02 per share
Price / Book120.00

Profitability

EPS (Most Recent Fiscal Year)($0.39)
Net Income$5.28 million
Net Margins-122.75%
Return on Equity-388.58%
Return on Assets-61.59%

Miscellaneous

Employees116
Outstanding Shares59,270,000

BioDelivery Sciences International (NASDAQ:BDSI) Frequently Asked Questions

What is BioDelivery Sciences International's stock symbol?

BioDelivery Sciences International trades on the NASDAQ under the ticker symbol "BDSI."

How were BioDelivery Sciences International's earnings last quarter?

BioDelivery Sciences International, Inc. (NASDAQ:BDSI) issued its quarterly earnings results on Thursday, May, 10th. The specialty pharmaceutical company reported ($0.18) earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of ($0.21) by $0.03. The specialty pharmaceutical company had revenue of $11.28 million for the quarter, compared to the consensus estimate of $10.77 million. BioDelivery Sciences International had a negative net margin of 122.75% and a negative return on equity of 388.58%. View BioDelivery Sciences International's Earnings History.

When is BioDelivery Sciences International's next earnings date?

BioDelivery Sciences International is scheduled to release their next quarterly earnings announcement on Tuesday, August, 7th 2018. View Earnings Estimates for BioDelivery Sciences International.

What price target have analysts set for BDSI?

6 brokers have issued 1 year price objectives for BioDelivery Sciences International's shares. Their predictions range from $3.50 to $5.00. On average, they expect BioDelivery Sciences International's stock price to reach $4.25 in the next year. View Analyst Ratings for BioDelivery Sciences International.

What are Wall Street analysts saying about BioDelivery Sciences International stock?

Here are some recent quotes from research analysts about BioDelivery Sciences International stock:
  • 1. HC Wainwright analysts commented, "Helm With Wind in Belbuca’s Sails; Reiterate Buy Stock Data 05/04/2018 Price $1.93 Exchange NASDAQ Price Target $4.00 52-Week High $3.50 52-Week Low $1.85 Enterprise Value (M) $146.4 Market Cap (M) $108 Shares Outstanding (M) 55.9 3 Month Avg Volume 373,600 Balance Sheet Metrics Cash (M) $21.2 Total Debt (M) $60.0 Total Cash/Share $0.38 EPS Diluted Full Year – Dec 2017A 2018E 2019E 1Q 0.91 (0.22) — 2Q (0.23) (0.18) — 3Q (0.18) (0.17) — 4Q (0.29) (0.16) — FY 0.21 (0.73) (0.39) Revenue ($M) Full Year – Dec 2017A 2018E 2019E 1Q 29.5 10.6 — 2Q 8.7 11.9 — 3Q 11.3 13.1 — 4Q 12.5 14.6 — FY 62.0 50.2 73.3 4 3.5 3 2.5 2 1.5 MAY-17 SEP-17 JAN-18 MAY-18 3 2.5 2 1.5 1 0.5 0 Vol. (mil) Price New CEO finally announced. BDSI announced the appointment of new CEO, Herm Cukier, ahead 1Q18 results reporting Thursday, May 10. Mr." (5/7/2018)
  • 2. Cantor Fitzgerald analysts commented, "Positives from the quarter: 1) BDSI announced it had secured preferred coverage for Belbuca with Humana (HUM, Neutral) effective March 1. Effective Jan. 1, 2018, United Healthcare (UNH, OW) removed step edits for Belbuca, and CVS/Caremark (CVS, Not covered) and ProCareRx moved Belbuca to a preferred position. Additionally, Belbuca and Butrans have been added to the Ohio Workers Comp formulary as preferred medications, effective 4/1/18; 2) Belbuca prescriptions grew 10% in 4Q17 vs. 3Q17, and have continued to grow in 2018; 3) Scott Plesha was appointed to the role of President; and 4) cash and equivalents totaled $21.9MM at 12/31/17, which should fund operations into 2H18. Management noted on the call that it could potentially qualify for an additional tranche of its loan agreement in 2018. Other levers the company has to decrease cash burn and extend the cash runway include better-than- expected sales, lower R&D and SG&A spending, and potential partnerships or divestments of the company’s other products." (3/15/2018)
  • 3. According to Zacks Investment Research, "BioDelivery has secured improved positioning in six new managed care contracts providing preferred access to its key drug, Bunavail, since July 2016. This is expected to boost the drug’s sales and profitability in turn. Meanwhile, its second marketed drug, Belbuca, recently received an approval in Canada for severe pain that should support further sales growth. BioDelivery’s shares have significantly outperformed the industry in the last one year. However, the company suffered a setback with the discontinuation of clonidine topical gel for management of painful diabetic neuropathy in December 2016. BioDelivery’s portfolio as well as its pipeline candidates may also face a severe competition as it targets a highly genericized and crowded market." (2/14/2018)

Who are some of BioDelivery Sciences International's key competitors?

Who are BioDelivery Sciences International's key executives?

BioDelivery Sciences International's management team includes the folowing people:
  • Dr. Francis E. O'Donnell Jr., M.D., Exec. Chairman (Age 68)
  • Dr. Mark A. Sirgo, Vice Chairman & Interim CEO (Age 64)
  • Mr. Ernest Robert De Paolantonio CPA, MBA, CFO, Corp. Sec. & Treasurer (Age 65)
  • Dr. Niraj Vasisht, CTO & Sr. VP of Product Devel. (Age 54)
  • Mr. Scott M. Plesha, Pres

Has BioDelivery Sciences International been receiving favorable news coverage?

Media headlines about BDSI stock have been trending somewhat positive this week, Accern Sentiment Analysis reports. The research group identifies positive and negative press coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. BioDelivery Sciences International earned a media sentiment score of 0.11 on Accern's scale. They also gave headlines about the specialty pharmaceutical company an impact score of 47.50 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company's share price in the immediate future.

Who are BioDelivery Sciences International's major shareholders?

BioDelivery Sciences International's stock is owned by many different of retail and institutional investors. Top institutional shareholders include venBio Select Advisor LLC (9.17%), BROADFIN CAPITAL, LLC (7.30%), BROADFIN CAPITAL, LLC (7.30%), BROADFIN CAPITAL, LLC (7.30%), Blair William & Co. IL (1.10%) and Hikari Power Ltd (0.86%). Company insiders that own BioDelivery Sciences International stock include Barry I Feinberg, Francis E Odonnell Jr, Mark A Sirgo, Niraj Vasisht, Paolantonio Ernest Robert De, Samuel P Sears, Jr and William B Stone. View Institutional Ownership Trends for BioDelivery Sciences International.

Which institutional investors are selling BioDelivery Sciences International stock?

BDSI stock was sold by a variety of institutional investors in the last quarter, including Blair William & Co. IL, Bailard Inc., Hikari Power Ltd and A.R.T. Advisors LLC. Company insiders that have sold BioDelivery Sciences International company stock in the last year include Francis E Odonnell Jr, Mark A Sirgo and Paolantonio Ernest Robert De. View Insider Buying and Selling for BioDelivery Sciences International.

Which institutional investors are buying BioDelivery Sciences International stock?

BDSI stock was acquired by a variety of institutional investors in the last quarter, including venBio Select Advisor LLC, Foresite Capital Management III LLC, Knott David M and GSA Capital Partners LLP. View Insider Buying and Selling for BioDelivery Sciences International.

How do I buy shares of BioDelivery Sciences International?

Shares of BDSI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is BioDelivery Sciences International's stock price today?

One share of BDSI stock can currently be purchased for approximately $2.40.

How big of a company is BioDelivery Sciences International?

BioDelivery Sciences International has a market capitalization of $148.18 million and generates $61.99 million in revenue each year. The specialty pharmaceutical company earns $5.28 million in net income (profit) each year or ($0.39) on an earnings per share basis. BioDelivery Sciences International employs 116 workers across the globe.

How can I contact BioDelivery Sciences International?

BioDelivery Sciences International's mailing address is 4131 PARKLAKE AVENUE SUITE 225, RALEIGH NC, 27612. The specialty pharmaceutical company can be reached via phone at 919-582-9050 or via email at [email protected]


MarketBeat Community Rating for BioDelivery Sciences International (BDSI)

Community Ranking:  3.3 out of 5 (star star star)
Outperform Votes:  368 (Vote Outperform)
Underperform Votes:  188 (Vote Underperform)
Total Votes:  556
MarketBeat's community ratings are surveys of what our community members think about BioDelivery Sciences International and other stocks. Vote "Outperform" if you believe BDSI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BDSI will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

BioDelivery Sciences International (NASDAQ:BDSI) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
6 Wall Street analysts have issued ratings and price targets for BioDelivery Sciences International in the last 12 months. Their average twelve-month price target is $4.25, suggesting that the stock has a possible upside of 77.08%. The high price target for BDSI is $5.00 and the low price target for BDSI is $3.50. There are currently 1 hold rating and 5 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.832.862.862.83
Ratings Breakdown: 0 Sell Rating(s)
1 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $4.25$4.4286$4.5714$4.50
Price Target Upside: 77.08% upside104.08% upside79.27% upside91.49% upside

BioDelivery Sciences International (NASDAQ:BDSI) Consensus Price Target History

Price Target History for BioDelivery Sciences International (NASDAQ:BDSI)

BioDelivery Sciences International (NASDAQ:BDSI) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/23/2018HC WainwrightLower Price TargetBuy ➝ Buy$4.00 ➝ $3.50LowView Rating Details
5/11/2018Roth CapitalSet Price TargetBuy$5.00 ➝ $4.00MediumView Rating Details
5/7/2018Cantor FitzgeraldSet Price TargetBuy$5.00HighView Rating Details
1/26/2018Seaport Global SecuritiesInitiated CoverageBuy ➝ Buy$5.00HighView Rating Details
10/22/2017Piper Jaffray CompaniesSet Price TargetBuy$4.00N/AView Rating Details
7/24/2017Janney Montgomery ScottBoost Price TargetBuy ➝ Fair Value$3.00 ➝ $4.00HighView Rating Details
5/16/2017FBR & CoSet Price TargetBuy$4.00MediumView Rating Details
(Data available from 5/26/2016 forward)

Earnings

BioDelivery Sciences International (NASDAQ:BDSI) Earnings History and Estimates Chart

Earnings by Quarter for BioDelivery Sciences International (NASDAQ:BDSI)

BioDelivery Sciences International (NASDAQ:BDSI) Earnings Estimates

2018 EPS Consensus Estimate: ($0.71)
2019 EPS Consensus Estimate: ($0.13)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20182($0.23)($0.21)($0.22)
Q2 20182($0.20)($0.16)($0.18)
Q3 20182($0.18)($0.14)($0.16)
Q4 20182($0.16)($0.13)($0.15)
Q1 20191($0.10)($0.10)($0.10)
Q2 20191($0.06)($0.06)($0.06)
Q3 20191($0.01)($0.01)($0.01)
Q4 20191$0.04$0.04$0.04

BioDelivery Sciences International (NASDAQ BDSI) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/7/2018($0.20)N/AView Earnings Details
5/10/2018Q1 2018($0.21)($0.18)$10.77 million$11.28 millionViewN/AView Earnings Details
3/15/2018Q4 2017($0.24)($0.29)$9.83 million$12.51 millionViewListenView Earnings Details
11/9/2017Q3 2017($0.22)($0.21)$9.40 million$11.25 millionViewN/AView Earnings Details
8/9/2017Q2 2017($0.23)($0.27)$8.45 million$8.70 millionViewListenView Earnings Details
5/15/2017Q1 2017$0.09$0.58$27.07 million$29.48 millionViewN/AView Earnings Details
3/17/2017Q4 2016($0.26)($0.2890)$6.37 million$3.90 millionViewN/AView Earnings Details
11/9/2016Q316($0.26)($0.30)$3.58 million$3.60 millionViewListenView Earnings Details
8/9/2016Q216($0.31)($0.31)$3.35 million$5.00 millionViewN/AView Earnings Details
5/10/2016Q116($0.35)($0.36)$2.96 million$3.00 millionViewListenView Earnings Details
3/10/2016Q415$0.55$0.19$52.40 million$32.20 millionViewListenView Earnings Details
11/9/2015Q315($0.34)($0.39)$1.56 million$1.20 millionViewN/AView Earnings Details
8/10/2015Q215($0.31)($0.37)$3.29 million$1.70 millionViewListenView Earnings Details
5/11/2015Q115($0.20)($0.16)$10.80 million$13.10 millionViewListenView Earnings Details
3/16/2015Q414($0.40)($0.51)$4.00 million$2.50 millionViewN/AView Earnings Details
11/5/2014Q3 2014($0.29)($0.39)$3.02 million$1.82 millionViewN/AView Earnings Details
8/7/2014Q2 2014($0.07)($0.14)$11.65 million$13.89 millionViewN/AView Earnings Details
5/9/2014Q114($0.15)($0.11)$11.60 million$20.69 millionViewN/AView Earnings Details
3/14/2014($0.22)($0.33)$4.88 million$3.97 millionViewN/AView Earnings Details
11/12/2013Q3 2013($0.32)($0.49)$2.68 million$3.00 millionViewN/AView Earnings Details
8/9/2013Q2 2013($0.34)($0.35)$1.79 million$2.76 millionViewN/AView Earnings Details
5/9/2013Q1 2013($0.42)($0.36)$1.36 million$1.62 millionViewN/AView Earnings Details
3/18/2013Q4 2012($0.18)$0.09ViewN/AView Earnings Details
11/8/2012Q3 2012($0.32)($0.64)ViewN/AView Earnings Details
8/9/2012Q2 2012$0.27$0.08ViewN/AView Earnings Details
5/10/2012Q1 2012$0.64$0.75ViewN/AView Earnings Details
3/19/2012Q4 2011($0.21)($0.16)ViewN/AView Earnings Details
11/14/2011Q3 2011($0.21)($0.17)ViewN/AView Earnings Details
5/13/2011Q1 2011($0.25)($0.34)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

BioDelivery Sciences International (NASDAQ:BDSI) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

BioDelivery Sciences International (NASDAQ BDSI) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 9.00%
Institutional Ownership Percentage: 46.14%
Insider Trading History for BioDelivery Sciences International (NASDAQ:BDSI)
Institutional Ownership by Quarter for BioDelivery Sciences International (NASDAQ:BDSI)

BioDelivery Sciences International (NASDAQ BDSI) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
4/10/2018Mark A SirgoDirectorSell100,000$2.06$206,000.002,585,966View SEC Filing  
4/6/2018Paolantonio Ernest Robert DeCFOSell64,155$2.09$134,083.9597,731View SEC Filing  
3/8/2018Francis E Odonnell JrDirectorSell113,876$2.14$243,694.64319,717View SEC Filing  
1/19/2018Mark A SirgoDirectorSell709,502$2.73$1,936,940.461,759,262View SEC Filing  
1/17/2018Mark A SirgoDirectorSell108,000$2.57$277,560.001,759,262View SEC Filing  
1/3/2018Mark A SirgoDirectorSell162,509$2.78$451,775.021,759,262View SEC Filing  
9/21/2017Mark A SirgoInsiderSell201,373$2.84$571,899.321,509,262View SEC Filing  
9/20/2017Mark A SirgoCEOSell65,405$2.75$179,863.751,509,262View SEC Filing  
9/19/2017Mark A SirgoCEOSell24,516$2.75$67,419.001,509,262View SEC Filing  
9/18/2017Mark A SirgoCEOSell6,000$2.85$17,100.001,509,262View SEC Filing  
9/15/2017Mark A SirgoCEOSell54,833$2.90$159,015.701,509,262View SEC Filing  
9/14/2017Mark A SirgoCEOSell50,000$2.95$147,500.001,509,262View SEC Filing  
3/31/2017Mark A SirgoCEOSell110,895$1.90$210,700.501,670,157View SEC Filing  
3/23/2017Francis E Odonnell JrDirectorSell750$1.90$1,425.00272,049View SEC Filing  
3/23/2017Niraj VasishtSVPSell530$1.90$1,007.00272,943View SEC Filing  
3/23/2017Paolantonio Ernest Robert DeCFOSell170$1.90$323.0096,634View SEC Filing  
1/30/2017Niraj VasishtInsiderSell6,905$1.91$13,188.55178,727View SEC Filing  
12/1/2016Samuel P. Sears, Jr.DirectorSell12,000$1.67$20,040.00View SEC Filing  
11/23/2016Barry I FeinbergDirectorBuy2,000$1.67$3,340.00View SEC Filing  
11/17/2016Barry I FeinbergDirectorBuy3,000$1.87$5,610.00View SEC Filing  
9/23/2016Francis E Odonnell JrDirectorSell100,000$2.57$257,000.00View SEC Filing  
9/23/2016Niraj VasishtInsiderSell47,000$2.43$114,210.0073,081View SEC Filing  
9/22/2016Paolantonio Ernest Robert DeCFOSell14,800$2.44$36,112.0014,866View SEC Filing  
8/25/2016Barry I FeinbergDirectorBuy2,500$2.55$6,375.00View SEC Filing  
8/11/2016William B StoneDirectorSell16,000$2.57$41,120.00122,675View SEC Filing  
3/21/2016Charles BramlageDirectorBuy8,850$2.82$24,957.0028,150View SEC Filing  
3/18/2016Barry I FeinbergDirectorBuy10,000$2.74$27,400.00View SEC Filing  
3/18/2016Niraj VasishtCTOBuy1,000$2.80$2,800.0068,420View SEC Filing  
3/17/2016Paolantonio Ernest Robert DeCFOBuy4,000$2.60$10,400.0013,383View SEC Filing  
11/24/2015Francis E Odonnell JrDirectorSell50,000$6.01$300,500.00View SEC Filing  
11/13/2015Thomas D'alonzoDirectorBuy4,528$5.52$24,994.5676,379View SEC Filing  
9/3/2015Francis E Odonnell JrDirectorSell20,000$6.43$128,600.00144,671View SEC Filing  
8/26/2015Paolantonio Ernest Robert DeCFOBuy1,650$6.20$10,230.009,383View SEC Filing  
8/13/2015William B StoneDirectorSell11,500$7.01$80,615.00View SEC Filing  
6/16/2015Francis E Odonnell JrDirectorSell21,597$8.03$173,423.91View SEC Filing  
6/16/2015Mark A SirgoCEOSell4,187$7.97$33,370.39View SEC Filing  
5/26/2015Barry I FeinbergDirectorBuy2,000$7.84$15,680.00View SEC Filing  
5/14/2015Barry I FeinbergDirectorBuy2,000$8.54$17,080.00View SEC Filing  
5/13/2015Thomas D'alonzoDirectorBuy6,226$8.07$50,243.82View SEC Filing  
12/26/2014Francis E Odonnell JrDirectorSell70,000$12.00$840,000.00View SEC Filing  
12/15/2014Mark A SirgoCEOBuy2,500$12.23$30,575.00View SEC Filing  
12/10/2014Samuel P Sears JrDirectorSell7,853$15.03$118,030.59View SEC Filing  
11/12/2014William B StoneDirectorSell14,000$16.11$225,540.00View SEC Filing  
9/4/2014Barry I FeinbergDirectorBuy1,000$15.18$15,180.00View SEC Filing  
9/4/2014Mark A SirgoCEOBuy2,000$15.04$30,080.00View SEC Filing  
8/27/2014Andrew L FinnEVPSell90,000$15.00$1,350,000.00View SEC Filing  
8/22/2014Charles BramlageDirectorBuy1,800$13.85$24,930.00View SEC Filing  
6/25/2014Paolantonio Ernest Robert DeCFOBuy1,250$12.13$15,162.50View SEC Filing  
6/12/2014Samuel P Sears JrDirectorSell5,000$12.33$61,650.00View SEC Filing  
6/11/2014Francis E Odonnell JrDirectorSell125,000$11.04$1,380,000.00View SEC Filing  
3/26/2014Francis Odonnell, Jr.DirectorSell50,000$8.04$402,000.00View SEC Filing  
3/20/2014Samuel Sears, Jr.DirectorSell4,000$9.00$36,000.0019,853View SEC Filing  
3/11/2014Andrew FinnEVPSell80,000$9.99$799,200.00660,450View SEC Filing  
3/11/2014William StoneDirectorSell35,000$10.00$350,000.0063,178View SEC Filing  
2/20/2014Andrew FinnEVPSell18,737$8.84$165,635.08740,450View SEC Filing  
2/20/2014Francis Odonnell, Jr.DirectorSell70,000$8.92$624,400.002,521,751View SEC Filing  
2/20/2014Mark SirgoCEOSell42,000$8.92$374,640.00913,250View SEC Filing  
1/24/2014Andrew FinnEVPSell143,679$9.03$1,297,421.37705,653View SEC Filing  
1/24/2014James McnultySVPSell89,223$8.73$778,916.7949,399View SEC Filing  
1/24/2014John SheaDirectorSell130,000$8.78$1,141,400.0013,305View SEC Filing  
1/24/2014Mark SirgoCEOSell116,253$9.01$1,047,439.53815,250View SEC Filing  
11/18/2013Mark SirgoCEOBuy2,337$4.29$10,025.73874,179View SEC Filing  
9/19/2013Francis Odonnell, Jr.DirectorSell95,000$5.36$509,200.003,121,751View SEC Filing  
9/11/2013Samuel P Sears JrDirectorSell2,000$5.37$10,740.00View SEC Filing  
9/9/2013Samuel P Sears JrDirectorSell7,500$5.05$37,875.00View SEC Filing  
8/26/2013Andrew FinnEVPBuy5,000$4.58$22,900.00775,653View SEC Filing  
8/16/2013Mark SirgoCEOBuy5,100$4.43$22,593.00871,842View SEC Filing  
8/15/2013William StoneDirectorSell6,825$4.44$30,303.0063,175View SEC Filing  
8/14/2013James McnultyCFOBuy5,000$4.50$22,500.0049,399View SEC Filing  
6/21/2013Mark A SirgoCEOBuy3,400$4.30$14,620.00View SEC Filing  
6/20/2013Francis E Odonnell JrDirectorSell72,689$4.36$316,924.04View SEC Filing  
6/5/2013Samuel P Sears JrDirectorSell5,000$4.42$22,100.00View SEC Filing  
12/21/2012Andrew L FinnEVPBuy3,000$3.85$11,550.00View SEC Filing  
12/21/2012Mark A SirgoCEOBuy4,975$4.02$19,999.50View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

BioDelivery Sciences International (NASDAQ BDSI) News Headlines

Source:
DateHeadline
$12.19 Million in Sales Expected for BioDelivery Sciences International, Inc. (BDSI) This Quarter$12.19 Million in Sales Expected for BioDelivery Sciences International, Inc. (BDSI) This Quarter
www.americanbankingnews.com - May 26 at 4:41 AM
Equities Analysts Issue Forecasts for BioDelivery Sciences International, Inc.s FY2018 Earnings (BDSI)Equities Analysts Issue Forecasts for BioDelivery Sciences International, Inc.'s FY2018 Earnings (BDSI)
www.americanbankingnews.com - May 24 at 8:36 AM
-$0.18 Earnings Per Share Expected for BioDelivery Sciences International, Inc. (BDSI) This Quarter-$0.18 Earnings Per Share Expected for BioDelivery Sciences International, Inc. (BDSI) This Quarter
www.americanbankingnews.com - May 24 at 1:16 AM
HC Wainwright Trims BioDelivery Sciences International (BDSI) Target Price to $3.50HC Wainwright Trims BioDelivery Sciences International (BDSI) Target Price to $3.50
www.americanbankingnews.com - May 23 at 1:35 PM
BioDelivery Sciences to Present at the Jefferies 2018 Global Healthcare ConferenceBioDelivery Sciences to Present at the Jefferies 2018 Global Healthcare Conference
finance.yahoo.com - May 23 at 8:49 AM
BDSI closes $50M equity financing – here’s what its board looks like nowBDSI closes $50M equity financing – here’s what its board looks like now
finance.yahoo.com - May 22 at 4:43 PM
BioDelivery Sciences Announces Closing of $50 Million Equity Financing and Appointment of Peter Greenleaf as Chairman of the BoardBioDelivery Sciences Announces Closing of $50 Million Equity Financing and Appointment of Peter Greenleaf as Chairman of the Board
finance.yahoo.com - May 22 at 8:56 AM
BioDelivery Sciences (BDSI) Prices $50M of Equity FinancingBioDelivery Sciences (BDSI) Prices $50M of Equity Financing
www.streetinsider.com - May 17 at 4:41 PM
BioDelivery Sciences Announces Pricing of $50 Million Equity FinancingBioDelivery Sciences Announces Pricing of $50 Million Equity Financing
www.nasdaq.com - May 17 at 9:20 AM
Seaport Global Securities Brokers Boost Earnings Estimates for BioDelivery Sciences International, Inc. (BDSI)Seaport Global Securities Brokers Boost Earnings Estimates for BioDelivery Sciences International, Inc. (BDSI)
www.americanbankingnews.com - May 17 at 8:00 AM
BioDelivery Sciences International (BDSI) Given a $4.00 Price Target by HC Wainwright AnalystsBioDelivery Sciences International (BDSI) Given a $4.00 Price Target by HC Wainwright Analysts
www.americanbankingnews.com - May 14 at 11:03 AM
BioDelivery Sciences International (BDSI) Given a $4.00 Price Target by Roth Capital AnalystsBioDelivery Sciences International (BDSI) Given a $4.00 Price Target by Roth Capital Analysts
www.americanbankingnews.com - May 11 at 8:05 PM
BioDelivery Sciences International (BDSI) Releases  Earnings Results, Beats Expectations By $0.03 EPSBioDelivery Sciences International (BDSI) Releases Earnings Results, Beats Expectations By $0.03 EPS
www.americanbankingnews.com - May 11 at 1:53 PM
Reader Inquiry: At 52-Week Lows Is BioDelivery Sciences A Viable Turnaround Play?Reader Inquiry: At 52-Week Lows Is BioDelivery Sciences A Viable Turnaround Play?
seekingalpha.com - May 11 at 10:12 AM
BioDelivery Sciences Internationals (BDSI) CEO Herm Cukier on Q1 2018 Results - Earnings Call TranscriptBioDelivery Sciences International's (BDSI) CEO Herm Cukier on Q1 2018 Results - Earnings Call Transcript
seekingalpha.com - May 11 at 10:12 AM
BioDelivery (BDSI) Q1 Earnings and Sales Beat EstimatesBioDelivery (BDSI) Q1 Earnings and Sales Beat Estimates
finance.yahoo.com - May 11 at 10:11 AM
Edited Transcript of BDSI earnings conference call or presentation 10-May-18 8:30pm GMTEdited Transcript of BDSI earnings conference call or presentation 10-May-18 8:30pm GMT
finance.yahoo.com - May 11 at 10:11 AM
BioDelivery: 1Q Earnings SnapshotBioDelivery: 1Q Earnings Snapshot
finance.yahoo.com - May 10 at 4:44 PM
BioDelivery Sciences Reports Positive First Quarter 2018 Financial Results and Provides Corporate UpdateBioDelivery Sciences Reports Positive First Quarter 2018 Financial Results and Provides Corporate Update
finance.yahoo.com - May 10 at 4:44 PM
Xiaflex & Sterile Injectables Drive Endo's (ENDP) Q1 EarningsXiaflex & Sterile Injectables Drive Endo's (ENDP) Q1 Earnings
finance.yahoo.com - May 10 at 4:44 PM
BioDelivery Sciences (BDSI) Q1 Earnings: What to Expect?BioDelivery Sciences (BDSI) Q1 Earnings: What to Expect?
finance.yahoo.com - May 8 at 4:44 PM
$10.77 Million in Sales Expected for BioDelivery Sciences International, Inc. (BDSI) This Quarter$10.77 Million in Sales Expected for BioDelivery Sciences International, Inc. (BDSI) This Quarter
www.americanbankingnews.com - May 8 at 2:30 AM
HC Wainwright Reaffirms "Buy" Rating for BioDelivery Sciences International (BDSI)HC Wainwright Reaffirms "Buy" Rating for BioDelivery Sciences International (BDSI)
www.americanbankingnews.com - May 7 at 4:27 PM
Cantor Fitzgerald Reiterates "$5.00" Price Target for BioDelivery Sciences International (BDSI)Cantor Fitzgerald Reiterates "$5.00" Price Target for BioDelivery Sciences International (BDSI)
www.americanbankingnews.com - May 7 at 3:17 PM
BRIEF-BioDelivery Sciences Appoints Herm Cukier As CEOBRIEF-BioDelivery Sciences Appoints Herm Cukier As CEO
www.reuters.com - May 7 at 9:48 AM
BioDelivery Sciences International (BDSI) Scheduled to Post Earnings on MondayBioDelivery Sciences International (BDSI) Scheduled to Post Earnings on Monday
www.americanbankingnews.com - May 7 at 3:46 AM
 Analysts Anticipate BioDelivery Sciences International, Inc. (BDSI) Will Announce Earnings of -$0.23 Per Share Analysts Anticipate BioDelivery Sciences International, Inc. (BDSI) Will Announce Earnings of -$0.23 Per Share
www.americanbankingnews.com - May 6 at 7:33 PM
BioDelivery Sciences International (BDSI) Upgraded to "Sell" by ValuEngineBioDelivery Sciences International (BDSI) Upgraded to "Sell" by ValuEngine
www.americanbankingnews.com - May 3 at 10:32 PM
BioDelivery Sciences International, Inc. (BDSI) Given Average Rating of "Buy" by BrokeragesBioDelivery Sciences International, Inc. (BDSI) Given Average Rating of "Buy" by Brokerages
www.americanbankingnews.com - May 3 at 12:19 PM
BioDelivery Sciences Confirms Receipt of Notice of Intent to Nominate Directors by Broadfin CapitalBioDelivery Sciences Confirms Receipt of Notice of Intent to Nominate Directors by Broadfin Capital
finance.yahoo.com - May 3 at 9:07 AM
BRIEF-Broadfin Says Delivered Letter To BioDelivery Sciences With Nominations For BoardBRIEF-Broadfin Says Delivered Letter To BioDelivery Sciences With Nominations For Board
www.reuters.com - May 1 at 4:40 PM
BioDelivery Sciences to Host Conference Call and Webcast Reporting First Quarter 2018 Financial Results on Thursday, May 10BioDelivery Sciences to Host Conference Call and Webcast Reporting First Quarter 2018 Financial Results on Thursday, May 10
finance.yahoo.com - April 30 at 10:16 AM
BioDelivery Sciences International, Inc. (BDSI) Expected to Announce Quarterly Sales of $10.77 MillionBioDelivery Sciences International, Inc. (BDSI) Expected to Announce Quarterly Sales of $10.77 Million
www.americanbankingnews.com - April 21 at 2:52 AM
 Brokerages Expect BioDelivery Sciences International, Inc. (BDSI) to Post -$0.23 Earnings Per Share Brokerages Expect BioDelivery Sciences International, Inc. (BDSI) to Post -$0.23 Earnings Per Share
www.americanbankingnews.com - April 19 at 3:10 PM
Recent Analysis Shows J.Jill, BankUnited, Toronto Dominion Bank, Adamis Pharmaceuticals, BioDelivery Sciences International, and First Solar Market Influences — Renewed Outlook, Key Drivers of GrowthRecent Analysis Shows J.Jill, BankUnited, Toronto Dominion Bank, Adamis Pharmaceuticals, BioDelivery Sciences International, and First Solar Market Influences — Renewed Outlook, Key Drivers of Growth
finance.yahoo.com - April 19 at 9:30 AM
BioDelivery Sciences International (BDSI) Upgraded by Zacks Investment Research to BuyBioDelivery Sciences International (BDSI) Upgraded by Zacks Investment Research to Buy
www.americanbankingnews.com - April 18 at 7:30 PM
Q1 2018 Earnings Estimate for BioDelivery Sciences International, Inc. (BDSI) Issued By William BlairQ1 2018 Earnings Estimate for BioDelivery Sciences International, Inc. (BDSI) Issued By William Blair
www.americanbankingnews.com - April 18 at 7:58 AM
Why Is BioDelivery Sciences (BDSI) Up 2.4% Since Its Last Earnings Report?Why Is BioDelivery Sciences (BDSI) Up 2.4% Since Its Last Earnings Report?
finance.yahoo.com - April 16 at 9:34 AM
BioDelivery Sciences International, Inc. (BDSI) Director Mark A. Sirgo Sells 100,000 SharesBioDelivery Sciences International, Inc. (BDSI) Director Mark A. Sirgo Sells 100,000 Shares
www.americanbankingnews.com - April 13 at 10:10 PM
BioDelivery Sciences International (BDSI) PT Set at $4.00 by HC WainwrightBioDelivery Sciences International (BDSI) PT Set at $4.00 by HC Wainwright
www.americanbankingnews.com - April 13 at 2:17 PM
BioDelivery Sciences International (BDSI) Given a $5.00 Price Target by HC Wainwright AnalystsBioDelivery Sciences International (BDSI) Given a $5.00 Price Target by HC Wainwright Analysts
www.americanbankingnews.com - April 10 at 11:38 PM
BRIEF-Broadfin Capital Reports 7.3 Pct Stake In Biodelivery SciencesBRIEF-Broadfin Capital Reports 7.3 Pct Stake In Biodelivery Sciences
www.reuters.com - April 10 at 9:28 AM
BioDelivery Sciences International, Inc. (BDSI) Receives Average Recommendation of "Buy" from BrokeragesBioDelivery Sciences International, Inc. (BDSI) Receives Average Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - April 8 at 7:33 AM
Paolantonio Ernest Robert De Sells 64,155 Shares of BioDelivery Sciences International, Inc. (BDSI) StockPaolantonio Ernest Robert De Sells 64,155 Shares of BioDelivery Sciences International, Inc. (BDSI) Stock
www.americanbankingnews.com - April 6 at 7:33 PM
 Analysts Expect BioDelivery Sciences International, Inc. (BDSI) Will Post Quarterly Sales of $11.04 Million Analysts Expect BioDelivery Sciences International, Inc. (BDSI) Will Post Quarterly Sales of $11.04 Million
www.americanbankingnews.com - April 4 at 2:32 AM
From BDSI to Red Hat: The Triangles top inside stock sales of 1Q2018From BDSI to Red Hat: The Triangle's top inside stock sales of 1Q2018
www.bizjournals.com - April 3 at 9:11 AM
BioDelivery Sciences International, Inc. (BDSI) Expected to Announce Earnings of -$0.23 Per ShareBioDelivery Sciences International, Inc. (BDSI) Expected to Announce Earnings of -$0.23 Per Share
www.americanbankingnews.com - April 2 at 5:16 PM
BioDelivery Sciences International, Inc. to Post Q1 2018 Earnings of ($0.23) Per Share, Seaport Global Securities Forecasts (BDSI)BioDelivery Sciences International, Inc. to Post Q1 2018 Earnings of ($0.23) Per Share, Seaport Global Securities Forecasts (BDSI)
www.americanbankingnews.com - March 26 at 1:06 AM
BioDelivery Sciences International, Inc. to Post FY2018 Earnings of ($0.70) Per Share, Cantor Fitzgerald Forecasts (BDSI)BioDelivery Sciences International, Inc. to Post FY2018 Earnings of ($0.70) Per Share, Cantor Fitzgerald Forecasts (BDSI)
www.americanbankingnews.com - March 23 at 10:56 AM
BioDelivery Sciences (BDSI) in Focus: Stock Moves 5.1% Higher - NasdaqBioDelivery Sciences (BDSI) in Focus: Stock Moves 5.1% Higher - Nasdaq
www.nasdaq.com - March 21 at 4:59 PM

SEC Filings

BioDelivery Sciences International (NASDAQ:BDSI) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

BioDelivery Sciences International (NASDAQ:BDSI) Income Statement, Balance Sheet and Cash Flow Statement

Chart

BioDelivery Sciences International (NASDAQ BDSI) Stock Chart for Saturday, May, 26, 2018

Loading chart…

This page was last updated on 5/26/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.